StoneRidge PMG Advisors LLC purchased a new stake in shares of Solventum Corporation (NYSE:SOLV – Free Report) during the third quarter, HoldingsChannel reports. The fund purchased 7,589 shares of the company’s stock, valued at approximately $669,000.
Other large investors have also made changes to their positions in the company. Brighton Jones LLC grew its position in shares of Solventum by 96.2% during the third quarter. Brighton Jones LLC now owns 7,038 shares of the company’s stock worth $620,000 after purchasing an additional 3,450 shares in the last quarter. Ethic Inc. raised its stake in Solventum by 12.1% during the 3rd quarter. Ethic Inc. now owns 10,648 shares of the company’s stock valued at $939,000 after purchasing an additional 1,150 shares during the period. Pictet Asset Management Holding SA raised its stake in Solventum by 15.5% during the 3rd quarter. Pictet Asset Management Holding SA now owns 30,935 shares of the company’s stock valued at $2,727,000 after purchasing an additional 4,146 shares during the period. Palisade Asset Management LLC lifted its holdings in Solventum by 6.4% in the 3rd quarter. Palisade Asset Management LLC now owns 3,038 shares of the company’s stock worth $268,000 after purchasing an additional 184 shares in the last quarter. Finally, Calamos Advisors LLC lifted its holdings in Solventum by 2.1% in the 3rd quarter. Calamos Advisors LLC now owns 17,929 shares of the company’s stock worth $1,580,000 after purchasing an additional 363 shares in the last quarter.
Solventum Price Performance
NYSE:SOLV opened at $90.34 on Monday. The company has a current ratio of 1.03, a quick ratio of 0.72 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $15.38 billion, a P/E ratio of 101.51, a P/E/G ratio of 1.31 and a beta of 0.69. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $94.16. The business’s 50-day moving average is $87.73 and its 200 day moving average is $78.70.
Solventum (NYSE:SOLV – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.11. The company had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.93 billion. Solventum had a return on equity of 25.03% and a net margin of 1.91%. The firm’s revenue was down 7.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.50 earnings per share. On average, equities research analysts forecast that Solventum Corporation will post 7.25 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. Canadian Imperial Bank of Commerce set a $35.00 price target on Solventum in a research note on Wednesday, October 28th. KeyCorp lifted their price objective on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Stifel Nicolaus boosted their target price on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Jefferies Financial Group reissued a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Finally, UBS Group upped their target price on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $90.27.
View Our Latest Stock Analysis on SOLV
Trending Headlines about Solventum
Here are the key news stories impacting Solventum this week:
- Positive Sentiment: Solventum earned $1.45 per share on $1.95 billion in revenue, beating consensus estimates of $1.34–$1.35 per share and $1.93 billion in sales. The company raised its 2026 adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 results
- Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an overweight rating; Wells Fargo increased its target to $95 while retaining an equal-weight rating. Jefferies raised its target to $98. Piper Sandler rating
- Neutral Sentiment: The company said the 7% year-over-year sales decline (organic sales down 2.8%) reflected, in part, a temporary ERP transition effect: customers had placed advance orders in the prior quarter ahead of the system cutover. Solventum also reported that its separation process was more than 90% complete. Q3 earnings and ERP impact
- Negative Sentiment: Despite the quarterly beat, revenue fell 7% year over year and EPS was down from $1.50 a year ago, highlighting ongoing comparisons and execution risks. Quarterly earnings details
Solventum Company Profile
Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024.
The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.
Solventum serves customers in the United States and international markets.
Featured Articles
- Five stocks we like better than Solventum
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
